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a b s t r a c t
CDC6 is essential for S-phase to initiate DNA replication. It also regulates M-phase exit by inhibiting the
activity of the major M-phase protein kinase CDK1. Here we show that addition of recombinant CDC6 to
Xenopus embryo cycling extract delays the M-phase entry and inhibits CDK1 during the whole M-phase.
Down regulation of endogenous CDC6 accelerates the M-phase entry, abolishes the initial slow and
progressive phase of histone H1 kinase activation and increases the level of CDK1 activity during the
M-phase. All these effects are fully rescued by the addition of recombinant CDC6 to the extracts.
Diminution of CDC6 level in mouse zygotes by two different methods results in accelerated entry into the
ﬁrst cell division showing physiological relevance of CDC6 in intact cells. Thus, CDC6 behaves as CDK1
inhibitor regulating not only the M-phase exit, but also the M-phase entry and progression via limiting the
level of CDK1 activity. We propose a novel mechanism of M-phase entry controlled by CDC6 and
counterbalancing cyclin B-mediated CDK1 activation. Thus, CDK1 activation proceeds with concomitant
inhibition by CDC6, which tunes the timing of the M-phase entry during the embryonic cell cycle.
& 2014 Elsevier Inc. All rights reserved.
Introduction
CDC6, or Cell Division Cycle 6 protein, a member of the family of
AAAþATPases, is an essential and highly regulated component of
the pre-replication complex required for loading MiniChromosome
Maintenance (MCM) proteins onto the DNA (Perkins and Difﬂey,
1998; Weinreich et al., 1999). In the majority of organisms only one
isoform of this protein is present. Mus musculus is the only
organism, in which the presence of two isoforms of this protein
was reported. Mouse isoforms of CDC6 are different variants of
transcripts, which most probably appeared as result of alternative
splicing. Variant 1 of cdc6 gene transcript (# NM 011799.2 GenBank)
was localized for the ﬁrst time in mouse Embryonic Stem Cells (ES;
Berger et al., 1999). Variant 2 was identiﬁed in the brain tissues of
mouse embryo at 12.5 day of development (Strausberg et al., 2002).
Variant 1 encodes isoform a, and variant 2 isoform b of Cdc6
protein. Both isoforms are highly homologous. In contrast to its
function during DNA synthesis the role of CDC6 in mitosis is much
less understood. It was shown that in yeast, CDC6 plays a dual role
in the cell cycle control and it’s over expression delays the M-phase
entry (Bueno and Russell, 1992). CDC6 interacts with CDK1 upon M-
phase exit; binding of CDC6 to CDK1 inhibits its kinase activity
participating to exit frommitosis. Deletion of CDC6 lacking the CDK-
interacting domain has no effect on DNA replication during S-phase,
but slows down the mitotic exit (Elsasser et al., 1996; Calzada et al.,
2001). However, these results were challenged by the experiments
showing that in yeast exit from mitosis occurs in the absence of
CDC6 (Archambault et al., 2003).
In HeLa cells CDC6 is phosphorylated during the M-phase by
Polo-like kinase 1 (Plk1) (Yim and Erikson, 2010). CDC6 associates
with Plk1 and localizes at the spindle pole in metaphase and central
spindle in anaphase. The increase in CDC6 phosphorylation correlates
with the increased level of Plk1; conversely CDC6 is hypopho-
sphorylated in Plk1-depleted cells. Phosphorylation of CDC6 by
Plk1 is required for its interaction with CDK1 and for CDK1 inhibition
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necessary for separase activation and exit from mitosis (Yim and
Erikson, 2010). Thus, CDC6 is clearly involved in CDK1 inactivation
upon M-phase exit (ibid.) and, at least in HeLa cells, does not seem to
be involved in regulation of earlier M-phase steps.
In mouse oocytes, CDC6 is necessary for the meiotic spindle
formation and normal chromatin condensation (Anger et al., 2005).
The involvement of CDC6 in spindle formation was also shown
recently in Xenopus oocytes (Narasimhachar et al., 2012). The
absence of CDC6 during oocyte maturation prevents DNA replica-
tion between two meiotic M-phases and its accumulation in MII-
arrested oocytes is required for their competence to replicate DNA
(Lemaitre et al., 2002; Whitmire et al., 2002). Thus, CDC6 is clearly
involved in M-phase regulation in Xenopus laevis. In search for M-
phase regulators in X. laevis we performed a proteomic screen to
identify CDK1 partners during MII-arrest and upon oocyte activa-
tion and we found that CDC6 is associated with CDK1 during MII,
when CDK1 remains stable (Marteil et al., 2012). This suggested to
us that CDC6 might interact with CDK1 not only upon its inactiva-
tion during the M-phase exit, but also during other steps of the cell
division. Thus, we asked whether CDC6 is involved in regulation of
CDK1 during early M-phase stages, and in temporal regulation of
mitotic divisions. In this study we prove the mitotic role of CDC6 as
a CDK1 inhibitor in cell-free Xenopus embryo extracts. We show
also that it regulates M-phase entry during the ﬁrst embryonic
division of mouse zygotes.
Material and methods
Xenopus egg collection and activation
X. laevis females were purchased from NASCO (Fort Atkinson,
WI, USA). Females were injected subcutaneously with human
chorionic gondotrophin (500 IU per female; Chorulon, Intervet,
Netherlands) and kept overnight at 21 1C in 110 mM NaCl.
Metaphase-arrested Xenopus eggs, collected from overnight
spawning after HCG injection, were dejellied with 2% L-cysteine
pH 7.81 in XB buffer (100 mM KCl, 1 mM MgCl2, 50 mM CaCl2,
10 mM HEPES, and 50 mM sucrose pH 7.6). Dejellied eggs were
washed in XB, activated with calcium ionophore A23187 at 0.5 mg/
ml until cortical contraction was observed, and then extensively
washed in XB.
Xenopus cell free extracts
Cytoplasmic extracts from calcium ionophore-activated embryos
before the ﬁrst embryonic mitosis were prepared according to
Murray (1991) with modiﬁcations made in our laboratory (Chesnel
et al., 2005). Embryos transferred into appropriate tubes (5 ml
ultraclear™ centrifuge tubes; Beckman Coulter, Roissy, France) and
incubated at 4 1C. 0.5 ml XB buffer was then added containing
protease inhibitors (10 mg/ml of each aprotinin, leupeptin, pepstatin,
chymostatin, and 0.1 mM AEBSF) with 25 mg/ml cytochalasin D.
Embryos were subjected to three consecutive centrifugations: a short
spin to remove XB excess, a crushing spin 10,000g at 4 1C for 10 min,
and a clariﬁcation 10,000g spin of the supernatant at 4 1C for 10 min.
The supernatant was then supplemented with drugs or recombinant
proteins and reincubated at 21 1C. Every 4 min, aliquots were taken
out and directly mixed with Laemmli buffer for Western blot
analyses. All aliquots were stored at 80 1C. For details of the
experimental procedure see Fig. 1 in Results section.
Expression and puriﬁcation of recombinant XlCDC6
Complementary DNA encoding wild-type X. laevis CDC6 was
ampliﬁed by Polymerase Chain Reaction (PCR) and subcloned
between Sal I/Not I restriction site pGEX-4T3 expression vector
(plasmid pGEX). Wild-type XCDC6 was produced as glutathione S-
transferase (GST) fusion proteins in bacteria (Furstenthal et al.,
2001). Escherichia coli bacteria of BL21 strain were transformed in
Lysogeny broth (LB) medium using plasmid pGEX-XCDC6 DNA or
pGEX DNA alone. Bacteria membrane was destabilized by thermal
shock to allow the plasmid incorporation. After incubation at 37 1C
for 30 min, bacterial culture was added to LB agar medium
containing ampicillin (0.1%) and then incubated over night at
37 1C. Resulting single bacterial colony was added to 5 ml of liquid
medium LB/ampicillin 0.1% and incubated over night at 37 1C with
constant agitation. 1 ml of liquid culture (BL21 pGEX and pGEX-
XCDC6) was then added to 100 ml of medium LB/ampicillin 0.1%
and incubated at 37 1C until reaching an optical density (at 600 nm
wavelength) between 0.6 and 0.8. BL21 cells were grown and
treated with isopropyl-1-thio-β galactoside 1 mM for 4 h at 37 1C
to induce expression of the recombinant protein (GST-XCDC6). The
cells were harvested by centrifugation, resuspended in lysis buffer
(10 mM sodium phosphate, pH 7.2, 0.5 M NaCl, 1 mM EGTA, 1 mM
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Fig. 1. Scheme of experiments.
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dithiothreitol, and 0.25% Tween 20) containing 0.2 mM phenyl-
methylsulfonyl ﬂuoride and protease inhibitors (10 μg/ml each of
pepstatin, chymostatin and leupeptin), drop-frozen in liquid
nitrogen and stored at 80 1C. To purify GST-XCDC6, bacterial
extracts were sonicated and centrifuged 10,000g for 20 min. The
bacterial supernatant was mixed with glutathione-sepharose pre-
washed with lysis buffer, and incubated with gentle agitation at
4 1C for 1 h. The GST-fusion protein/glutathione-sepharose bead
complexes were then loaded into glutathione-sepharose resin
column and washed with lysis buffer (pH 8) containing reduced
glutathione (10 mM). Afterwards, the adsorbed proteins were
eluted and the fractions containing GST-fusion proteins were
collected, pooled and dialyzed against 10 mM 4-(2-hydro-
xyethyl)-1 piperazineethanesulfonic acid (HEPES)–KOH, pH 7.4,
150 mM NaCl, 0.1 mM DTT and 0.2 mM PMSF. Finally, the puriﬁed
fraction was frozen at 80 1C. This recombinant protein was used
for polyclonal antibody production in rabbits and this anti-XlCDC6
was used throughout this study.
CDC6 immunodepletion
Immunodepletion of CDC6 from Xenopus egg extracts was
carried out using AfﬁPrep Protein A beads (Sigma) conjugated
with the anti-CDC6 or with the preimmune serum overnight in
4 1C. 200 ml of beads were washed four times with XB buffer (pH
7.6) and incubated with 400 ml premitotic Xenopus embryo
extracts. After 30 min of incubation at 4 1C, extracts were centri-
fuged, beads were removed and supernatant was recovered. Two
consecutive runs of immunodepletion were required to remove
90% of CDC6.
Immunoblotting of X. laevis proteins
Extracts were subjected to 8% to 12.5% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970).
Separated proteins were transferred from the gel to nitrocellulose
membranes (Hybond C, Amersham Biosciences). Membranes were
blocked with PBS containing 5% non-fat dry milk and 0.1% Tween
20 and probed with primary antibodies against Cdc27, Cyclin B2,
β-Tubulin. Antigen–antibody complexes were revealed using alka-
line phosphatase-conjugated antirabbit or antimouse secondary
antibodies and detected by chemiﬂuorescence using the ECF
Reagent (Amersham Biosciences). Signal quantiﬁcation was per-
formed using ImageQuant 5.2 software (Amersham Biosciences).
For technical reasons some experiments were bloted on different
membranes. When a compilation of two separate membranes is
shown (Fig. 9A and B) it is clearly indicated by the blank
separating the two membranes.
Histone H1 kinase activity assay
Samples of Xenopus egg extracts were diluted in MPF buffer
supplemented with 0.5 mM sodium orthovanadate and 5 μg/μl of
leupeptin, aprotinin, pepstatin and chymostatin and containing
0.4 mg/ml H1 histone (type III-S), 1 μCi [γ32P] ATP (speciﬁc
activity: 3000 Ci/mmol; Amersham Biosciences) and 0.8 mM ATP.
After incubation at 30 1C for 30 min, phosphorylation reactions
were stopped by adding Laemmli sample buffer, heated at 85 1C
for 5 min. Histone H1 was separated by SDS-PAGE and incorpo-
rated radioactivity was measured by autoradiography of the gel
using a STORM phosphorimager (Amersham Biosciences) followed
by data analysis with ImageQuant 5.2 software.
Mouse zygotes
Ethical approval for presented studies on mouse embryos was
obtained from the Local Ethic Committee No 1 in Warsaw.
Embryos used in all experiments described below were obtained
from F1 (C57BL/6TarCBA/Tar) females. All chemicals, if not
stated otherwise, were purchased from Sigma-Aldrich.
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Collection of zygotes
One-cell embryos were obtained from females stimulated to
superovulation by the injection of pregnant mare serum gonado-
trophin (PMSG; 10 IU; Folligon, Intervet, Netherlands) followed by
the injection of human chorionic gondotrophin (hCG; 10 IU;
Chorulon, Intervet, Netherlands). Females were mated with F1
(C57BL/6TarCBA/Tar) males immediately after injection of hCG.
The time of hCG injection (hours post-hCG injection, h post hCG)
was the reference point for estimating the progression of the cell
cycle. Covered females were killed by cervical dislocation 27 h post
hCG. Isolated oviducts were placed in hyaluronidase (300 μg/ml)
and the zygotes were released from the ampullae. The follicular
cells, still accompanying the zygotes, dispersed in hyaluronidase
within 1–2 min. Follicular cells-free zygotes were collected in M2
medium (Fulton and Wittingham, 1978).
Norcantharidin treatment and scoring for the M-phase entry
Control zygotes were transferred into individual microdrops of
M2 covered with mineral oil. Experimental embryos were washed
in M2 supplemented with Norcantharidine (100 μg/ml) and trans-
ferred into individual microdrops of this medium under mineral
oil. Only these zygotes, in which both pronuclei were clearly
visible under inverted microscope, were subjected to in vitro
culture (37.5 1C, 5% CO2 in the air). To estimate the number of
embryos entering the ﬁrst mitosis they were observed under
inverted microscope every 30 min starting from 28 h post hCG.
Western blot of mouse zygotes
260 Zygotes were placed in 10 ml Laemmli buffer and the
samples were migrated in 15% PAGE. The Western blot analysis
was done as in the case of Xenopus proteins (above).
Injection of zygotes with antibodies
To diminish the amount of functional CDC6, zygotes obtained
as it was described above 20–21 h post hCG, were subjected to the
microinjection of speciﬁc anti-Cdc6 antibody (monoclonal mouse
IgG, undiluted commercial solution; Molecular Probes, Eugene,
USA). Microinjections were performed in M2 medium using
Eppenedorf microinjector 5542 (Eppenedorf–Netheler–Hinz
GmbH, Germany). The amount not exceeding 20 pl of anti-CDC6
antibody was microinjected into the cytoplasm of each zygote. The
zygotes microinjected with antibody against one of the member of
MCM family proteins, i.e. Mcm7 protein, irrelevant to the M-phase
entry, (polyclonal goat IgG, undiluted commercial solution; Santa
Cruz Biotechnology Inc., USA) served as a control group. Success-
fully injected zygotes from both groups were cultured in vitro in
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M2, under standard culture conditions (see above). To estimate the
number of embryos entering the ﬁrst mitosis they were observed
under inverted microscope every 30 min. starting from 28 h post
hCG. Difference between the treatment and control groups were
calculated using chi square test with Yates correction (SigmaStat
3.5). Po0.05 was considered statistically signiﬁcant.
Results
CDC6 has opposite effect to cyclin B and delays M-phase in X. laevis
embryo cycling extract
If CDC6 were involved in the regulation of the mitotic M-phase
entry as CDK1 inhibitor it should have an opposite effect on
M-phase progression than cyclin B, a CDK1 activator. To test
this hypothesis we added to the cycling extracts before entry into
the ﬁrst embryonic M-phase (see Fig. 1 for the scheme of the
experimental procedure) either GST alone (control), or recombi-
nant GST-CDC6 (20 nM ﬁnal concentration in the extract) or low
quantity of non-degradableΔ90 cyclin B from sea urchin (5 nM) or
both GST-CDC6 and Δ90 cyclin B (inhibitor and activator). We
also veriﬁed that the same extract incubated in different tubes
without addition of any recombinant protein or with the same
recombinant protein enters the M-phase rigorously at the same
time (data not shown). The extracts were incubated at 21 1C and
samples were collected every 4 min for Western blot analyses with
anti-CDC27 antibody. The CDC27 is a subunit of the APC/C, which
is a direct substrate of CDK1. On Western blot, the phosphorylation
of CDC27 is indicated by the presence of an up-shifted band and
thus indicates CDK1 activation (Huang et al., 2007). In GST-
supplemented control extract, the up-shift of CDC27 appeared at
24th minute of incubation (Fig. 2A). Cyclin Δ90 accelerated by
4 min the appearance of phosphorylated form of CDC27, while
20 nM GST-CDC6 inhibited CDC27 phosphorylation during the
whole duration (36 min) of the experiment. However, Δ90 cyclin
B and GST-CDC6 when added together, partially rescued CDC27
phosphorylation (the up-shifted band became visible after 28 min
of incubation (Fig. 2A, bottom row). Therefore, GST-CDC6 has an
opposite effect than CDK1 activator Δ90 cyclin B, and delays the
timing of mitotic entry through the inhibition of CDK1. The
quantiﬁcation of CDC27 phosphorylation is shown in Fig. 2B. To
ascertain that GST-CDC6 alone delays but does not completely
inhibit the M-phase entry, the experiment with 10 nM GST-CDC6
and 10 nM GST was performed and the samples were collected at
different time points during 78 min. Fig. 2C shows that Δ90 cyclin
B accelerates CDC27 phosphorylation as compared to 10 nM GST-
supplemented extract, while 10 nM GST-CDC6 delays phosphor-
ylation. The ﬁrst sign of CDC27 phosphorylation or the presence of
upshifted band was observed between 62 and 66 min. The mixture
ofΔ90 cyclin B and GST-CDC6 accelerates the process as compared
to GST-CDC6-supplemented extract (the upshift of CDC27 band
shows up between 58 and 62 min; Fig. 2C). GST-CDC6 was added
in different concentrations in 8 independent experiments andΔ90
cyclin B in three with always the same effect: GST-CDC6 delays
and Δ90 cyclin B accelerates the CDC27 phosphorylation and
thus the M-phase entry. Thus Δ90 cyclin B accelerates, while GST-
CDC6 deﬁnitely delays the M-phase entry. These experiments
conﬁrmed that exogenous CDC6 has the opposite action to Δ90
cyclin B.
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The cooperation between CDC6 and accumulating cyclin B determines
the timing of M-phase entry
To investigate if the GST-CDC6 modiﬁes the histone H1 kinase
activity and how it inﬂuences mitotic progression, we repeated the
above experiments and measured histone H1 kinase activity and
assessed cyclin B accumulation and degradation by quantifying the
levels of endogenous cyclin B2. The changes in dynamics of H1
kinase activity and quantity of cyclin B2 are presented in Fig. 3.
Δ90 cyclin B (5 nM) accelerates the peak of histone H1 kinase,
while GST-CDC6 (10 nM) delays it. The mixture of these two
proteins induces the peak of H1 kinase in an intermediate time
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point (Fig. 3). The comparison of levels of endogenous cyclin B2
and of histone H1 kinase shows that both Δ90 cyclin B and GST-
CDC6 modify temporal relationship between the peak of cyclin B2
and the peak of histone H1 kinase activity. In the control, the peak
of histone H1 kinase occurs 8 min after the peak of cyclin B2
accumulation (Fig. 3, the ﬁrst row). Acceleration of histone H1
kinase activation by Δ90 cyclin B results in shortening of this lag
period to 4 min (Fig. 3second row). In the presence of 10 nM GST-
CDC6 the lag period increases to 12 min (Fig. 3, the third row).
When Δ90 cyclin B and GST-CDC6 were added together, the lag
period (8 min) was the same like in control extracts (Fig. 3, the
bottom row) despite the fact that the M-phase was signiﬁcantly
delayed in comparison to the control. This type of experiment was
repeated 3 times in three independent extracts. This experiment
conﬁrmed that CDC6 delays M-phase entry in competition with
cyclin B and indicated that the CDC6 levels inﬂuence also the
timing of M-phase progression through the modiﬁcation of tem-
poral relationship between cyclin B accumulation and histone H1
kinase activation.
Because of high number of analyzed samples the values pre-
sented in Fig. 3A were obtained from different Western blots and
different histone H1 kinase reactions, respectively. These data were
useful for the comparison of temporal relationships between the
levels of cyclin B accumulation and histone H1 kinase activity, but
not for the comparison of real values obtained in all experimental
variants. To accurately analyze the relationship between levels of
cyclin B accumulation and histone H1 kinase activity we compared
the respective maximums on a single Western blot and in a single
H1 kinase reaction. The highest level of cyclin B2 accumulation and
the highest histone H1 kinase activity were found in the presence of
GST-CDC6 and they were allotted a 100% value (Fig. 3B and C). The
proﬁle of histograms is very similar for Fig. 3B and C (low for control
and Δ90 cyclin B, high for two GST-CDC6 containing samples).
However, the proportions between the low and high cyclin B2
peaks and respective histone H1 kinase peaks are not the same.
Namely, the differences between samples without GST-CDC6 and
with GST-CDC6 is clearly higher for cyclin B2 levels (about 42%)
than for histone H1 kinase (about 28%; compare double arrows on
the right of each Fig. 3B and C). This, most probably, results from the
diminution of histone H1 kinase activity by GST-CDC6. To ascertain
that CDC6 has an inhibitory action on histone H1 kinase activity we
measured this activity in CSF extract supplemented with 10 nM
GST-CDC6. Supplementary materials Fig. 1 shows that the recombi-
nant GST-CDC6 indeed lowers histone H1 kinase activity. In
summary, this experiment conﬁrms that CDC6 not only inhibits
the process of histone H1 kinase activation upon M-phase entry, but
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also moderates the histone H1 kinase activity when M-phase is fully
engaged. The apparent paradox that the histone H1 kinase activity
is the highest in the presence of CDC6 acting as CDK1 inhibitor can
be explained by the fact that this maximal activity appears much
later than in the control (24 min. difference; i.e. 74 min. in the
presence of GST-CDC6 (see Fig. 3A third row) vs. 50 min. in the
control (see Fig. 3A, ﬁrst row). During this additional period the
endogenous cyclin B accumulates and its threshold level necessary
to trigger the M-phase becomes higher than in the control con-
tributing to the increase in histone H1 kinase activity. Noteworthy,
the acceleration of the M-phase with Δ90 cyclin B addition is
exactly the same in the control extract (Fig. 3A, arrow in second
row) and in the presence of GST-CDC6 (Fig. 3A, arrow in fourth
row). This shows that in these two cases the equilibrium permitting
M-phase entry is established, however, the level of endogenous
cyclin B is higher in the GST-CDC6-supplemneted extract due to the
delay provoked by the recombinant protein. Thus, GST-CDC6
inhibits CDK1, but the effect of this inhibition is not visible as a
direct difference in histone H1 kinase activity because it is attenu-
ated by the continuous cyclin B2 accumulation.
Norcantharidin diminishes CDC6, accelerates mitotic M-phase
and removes initial slow step of CDK1 activation
We next inhibited endogenous CDC6 in the extracts using
Norcantharidin (NCTD), which induces degradation of CDC6
during S-phase in mammalian cells (Li et al., 2006, 2010). First
we checked whether NCTD induces CDC6 degradation in Xenopus
cell-free extracts. We added 100 mM NCTD or DMSO (control) to
the cycling extract and followed CDC6 levels using anti-CDC6
antibody (Fig. 4A) and the dynamics of M-phase entry using anti-
CDC27 antibody on Western blots (Fig. 4B). In the control, CDC6
level slightly increased during 40 min incubation (10%), while in
the presence of NCTD the CDC6 level dropped to about 70% as
compared to the control (Fig. 4A). Thus, NCTD signiﬁcantly
diminishes CDC6 level in X. laevis cell-free extract. CDC27 Western
blot showed that concomitantly NCTD accelerated the M-phase
entry by 12 min as compared to the control (Fig. 4B). To further
characterize the NCTD effect on M-phase progression we repeated
the experiment 7 times and analyzed CDC27 up shift and histone
H1 kinase activity. As shown in Fig. 4C the appearance of the
CDC27 up-shift is accelerated, and shows faster dynamics in the
presence of 100 mM NCTD than in the control. Similar changes
were observed for histone H1 kinase activity (Fig. 4D). Most
interestingly, we noticed that NCTD reduced greatly the initial
slow phase of histone H1 kinase activation (arrows in Fig. 4D).
Thus, CDC6 diminution correlates not only with acceleration of the
M-phase initiation, but also with the increased dynamics of CDK1
activation suggesting that endogenous CDC6 regulates these
processes.
In another set of experiments we used increasing concentrations
of NCTD (50, 100 and 150 mM) and observed that the dynamics of
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CDC27 phosphorylation (Fig. 5A) and histone H1 kinase activation
(Fig. 5B) were accelerated in a dose-dependent manner. In addition,
the increase in NCTD concentration provoked shortening of the
initial phase of histone H1 kinase activation (Fig. 5B, arrows). When
we compared the real values of histone H1 kinase activity during
the M-phase in control and 150 mM NCTD-treated extracts in a
single reaction we found that the activity in NCTD-treated extract
was much higher than in the control (Fig. 5C). CDC6 levels
decreased in dose-dependent manner when NCTD concentration
was raised in the extracts, while histone H1 kinase increased
accordingly (Fig. 5D and E). These results show that NCTD provokes
CDC6 diminution, which correlates with acceleration of M-phase
entry and the increase in histone H1 kinase activity.
GST-CDC6 rescues the timing and the slow step of CDK1 activation
upon M-phase entry in presence of NCTD
To rescue the phenotype of the M-phase induced by NCTD, we
added recombinant GST-CDC6 to the cycling extract supplemented
with 100 mM NCTD. The timing of CDC27 phosphorylation (Fig. 6A)
and histone H1 kinase activation and progression was rescued
(Fig. 6B, horizontal arrows) by 5 nM GST-CDC6. Moreover, the initial
slow phase of histone H1 kinase activation was restored (Fig. 6B,
vertical arrows). However, the levels of histone H1 kinase were not
rescued under the above conditions and they were higher in the
presence of NCTD and NCTDþGST-CDC6 than in control even when
the levels of endogenous cyclin B2 were lower in these experi-
mental variants due to acceleration of the M-phase entry (Fig. 6C
and D). To further analyze the effects of NCTD in relation to CDC6
we repeated the above experiment with two doses of GST-CDC6 (10
and 20 nM). The increase in CDC6 level delayed CDC27 phosphor-
ylation (Fig. 7A) and histone H1 kinase dynamics (Fig. 7B) in a dose-
dependent manner rescuing the accelerated phenotype induced by
NCTD. However, the comparison of histone H1 kinase activity in the
control and NCTDþ20 nM GST-CDC6 treatment shows that this
activity was much higher in the presence of NCTD (Fig. 7C). Thus,
GST-CDC6 allows the rescue of the timing of M-phase events, but
not of histone H1 kinase activity. Further analysis by Western blot
showed, as expected, that the peaks of cyclin B2 accumulation were
the highest in the experimental variants in which the M-phase
appeared the latest, i.e. in the presence of 20 nM GST-CDC6 and in
the control; Fig. 7D). The comparison of endogenous CDC6 levels
and histone H1 kinase activity showed the inverse correlation
(Fig. 7E and F). The quantiﬁcation of GST-CDC6 added to the extracts
showed that this recombinant protein also was destabilized by
NCTD and decreased in quantity during incubation of extracts
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(Fig. 7G and H). These data suggest that the rescue of the histone H1
kinase activity could be prevented by the diminution of recombi-
nant CDC6 in the extract.
Anti-CDC6 accelerates M-phase entry and removes initial step
of CDK1 activation
In a search for more speciﬁc approach to interfere with CDC6
activity we tested the effect of anti-CDC6 antibody. Cell-free extract
was supplemented with the preimmune or immune serum at 1:100
dilutions. As shown in Fig. 8A the timing of phosphorylation of
CDC27 was accelerated in extract supplemented with the anti-CDC6
antibody as compared to the control. We next compared the effect of
anti-CDC6 and the mixture of anti-CDC6 and GST-CDC6 (10 and
20 nM). The experiment showed that anti-CDC6 alone accelerated
the M-phase entry as in the experiment shown in Fig. 8A. GST-CDC6
delayed the timing of M-phase when added to the extract together
with anti-CDC6. 10 nM GST-CDC6 rescued the M-phase timing, while
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20 nM GST-CDC6 delayed it even further (Fig. 8B). The comparison of
proﬁles of histone H1 kinase activity and of cyclin B2 accumulation
showed the same tendencies as in previously described experiments
of the rescue of NCTD effects by GST-CDC6 (Fig. 8C). The maximum of
cyclin B2 accumulation was slightly higher in the presence of GST-
CDC6 in comparison to the control and anti-CDC6 alone in accord
with the slight delay in M-phase entry (28 vs. 24 min; Fig. 8D).
However, in contrast to previously described experiments with
NCTD, the levels of CDC6 remained high in all experimental variants,
in which the anti-CDC6 was used as an agent interfering with
endogenous CDC6 function (Fig. 8E). Despite the rescue of the timing
and dynamics of the M-phase, the histone H1 kinase activities in
extracts supplemented with anti-CDC6 in conjunction with two
doses of GST-CDC6 were clearly lower than in the control and in
the presence of anti-CDC6 alone (Fig. 8F). This conﬁrms the inhibitory
effect of CDC6 on CDK1 showing that anti-CDC6 effectively increase,
while GST-CDC6 diminishes histone H1 kinase activity.
Depletion of CDC6 modiﬁes the M-phase similarly to NCTD and
anti-CDC6, but GST-CDC6 fully rescues these changes
CDC6 was immunodepleted from the extract using anti-CDC6
antibody (Fig. 9A). In the absence of CDC6 the phosphorylation of
CDC27 was accelerated. The addition of GST to CDC6-depleted
extract did not change this timing, which remained accelerated in
comparison to the control (Fig. 9B). However, 10 nM GST-CDC6
addition rescued the timing of CDC27 phosphorylation, while
20 nM GST-CDC6 delayed it further (Fig. 9B). Proﬁles of histone
H1 kinase activity and cyclin B2 accumulation conﬁrmed these
results and showed that GST-CDC6 rescues the phenotype induced
by CDC6 depletion (Fig. 9C). The levels of maximal accumulation of
cyclin B2 were slightly higher in GST-CDC6-supplemented extracts
in which M-phase was delayed (Fig. 9D). Most importantly, the
maximum of histone H1 kinase activity were very similar in
control and extracts rescued by GST-CDC6 (Fig. 9E). These results
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clearly demonstrate that CDC6 regulates M-phase entry and
progression by inhibiting histone H1 kinase and counterbalancing
activating effects of cyclin B on CDK1.
Diminution of CDC6 in mouse zygotes results in earlier M-phase entry
To verify whether CDC6 plays a physiological role in the control
of timing of M-phase entry in intact cells we used mouse zygotes.
To test this we looked for a method which allowed us to lower
CDC6 level during a relatively short period between the S- and M-
phase. As we observed that NCTD provoked a very rapid CDC6
diminution in X. laevis cell-free extract, we assayed for the CDC6
levels by Western blot in mouse zygotes treated with 100 mM
NCTD. Indeed, 3-h incubation was sufﬁcient to provoke substantial
diminution of CDC6 (Fig. 10). Next we scored such zygotes for the
timing of the ﬁrst embryonic M-phase entry. The results shown in
Fig. 11A show a clear acceleration of the ﬁrst mitosis correlated
with the NCTD treatment and CDC6 diminution at the end of the
ﬁrst cell cycle. These results suggest that the mechanism of CDC6-
mediated inhibition towards CDK1 described by us in the cell-free
extract of X. laevis embryos operates also in intact mouse embryo-
nic cells. To ascertain that the results observed in the presence of
NCTD are speciﬁc for CDC6 diminution and not a side effect of the
drug, we interfered with functions of endogenous CDC6 by
injection of anti-CDC6 antibody to late zygotes and following
them for the timing of the ﬁrst mitotic M-phase entry. As the
injection procedure modiﬁes the timing of early development, we
compared this group of zygotes with controls injected with anti-
MCM7 antibody, irrelevant to the M-phase initiation. The compar-
ison of the dynamics of M-phase entry in the two groups is shown
in Fig. 11B. As in the case of NCTD incubation, the anti-CDC6-
injected zygotes entered the ﬁrst mitosis earlier than those
injected with anti-MCM7. These results show that the interference
with endogenous CDC6 by two different methods results in
acceleration in the M-phase entry similarly to the interference
with CDC6 levels in Xenopus cell-free extracts.
Discussion
We show here for the ﬁrst time that CDC6 inhibits histone H1
kinase activity upon CDK1 activation during M-phase entry and
delays the mitotic entry. The effect of CDC6 is opposite to the
activating action of cyclin B on CDK1. Previous studies have shown
the involvement of CDC6 in M-phase regulation, but only
described the role of CDC6 in G2/M checkpoint before entry into
the M-phase (Clay-Farrace et al., 2003) and upon the M-phase exit
(Calzada et al., 2001; Yim and Erikson, 2010). Thus, our data, for
the ﬁrst time, describe the role of CDC6 in the M-phase entry and
progression before the exit.
We propose a new model of M-phase entry in which CDC6
inhibits CDK1 to slow down its activation by cyclin B (Fig. 12). We
postulate that at the end of G2, the ﬁrst CDK1 active molecules
appearing due to the CDK1 Thr14 and Tyr15 dephosphorylation by
CDC25 are inhibited by CDC6 protein (Fig. 12, step1). The increase
in the number of active CDK1 molecules cannot be totally counter-
balanced by CDC6 inhibition and the low CDK1 activity appears
after a short period of inhibition by CDC6 (Fig. 12, step2). Thus, the
earliest appearance of CDK1 activity, which can be measured in a
histone H1 kinase assay, is determined not only by the threshold
level of cyclin B accumulation, but also by CDC6-dependent
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Fig. 10. NCTD provokes rapidly substantial diminution in CDC6a and b level in
mouse zygote prior the ﬁrst mitosis entry. 260 zygotes were incubated in 100 mM
NCTD for 3 h prior the ﬁrst mitosis. Samples were run on PAGE, immunobloted and
revealed with anti-MmCDC6 antibody. Speciﬁc diminution of CDC6 a and b bands is
observed in NCTD-treated zygotes. Higher and lower MW bands do not change and
serve as loading controls. Additionally, the equal loading was conﬁrmed by Ponceau
red staining of the membrane (not shown).
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inhibition. Our paper is the ﬁrst demonstration of an involvement
of equilibrium between cyclin B and CDC6 involved in triggering
the M-phase entry. During this early period, the histone H1 kinase
activity is steadily and slowly increasing due to continuous cyclin B
synthesis and association with CDK1. However, the dynamics of
this initial increase in histone H1 kinase activity is strictly
controlled by the inhibitory action of CDC6. The decrease in
CDC6, as in our experiments using NCTD, anti-CDC6 or CDC6
depletion speeds up M-phase entry abolishing the slow and
progressive step of CDK1 activation. The progressive increase in
histone H1 kinase may be of great importance for the normal M-
phase progression since it may allow progressive chromosome
condensation as well as of other early mitotic modiﬁcations, e.g.
microtubules. In the absence, or upon down regulation of CDC6
this initial step is absent and histone H1 kinase is activated
immediately upon M-phase entry. Such abrupt increase of histone
H1 kinase during mitosis could result in abnormal structure of
chromosomes and non-functional spindle assembly and for these
reasons controlled activation may be important. Slightly later,
when CDK1-cyclin B levels reach a threshold sufﬁcient to trigger
the CDK1/CDC25 activating loop (so called MPF, or M-phase
Promoting Factor activating loop), CDC6-dependent inhibition is
overcome and the massive activation of CDK1 takes place. How-
ever, the comparison of histone H1 kinase activity during the peak
in control extract and in extracts in which CDC6 was compromised
shows that even at that point, when the maximum of histone H1
kinase activity is achieved, CDC6 still acts as CDK1 inhibitor and
moderates its activity (Fig. 12, step3). Thus, during the whole M-
phase duration the levels of histone H1 kinase activity are system-
atically diminished via CDC6-dependent inhibition. This is an
unexpected and important conclusion because, it was believed
so far that the peak of histone H1 kinase represents the maximum
of CDK1 activity determined by the amount of accessible cyclin B.
We thus show here that CDK1 activity is moderated and remains
under control of CDC6 even during its peak of activation. If the
inhibitory effect of CDC6 on CDK1 described by Yim and Erikson
(2010) during M-phase exit in HeLa cells is also operational in
Xenopus embryonic mitosis, which we did not study here, it
would mean that CDC6 controls CDK1 level before, during and at
the end of M-phase and that this protein is a major inhibitor of
CDK1 during the whole M-phase. In addition, our results obtained
with mouse zygotes demonstrate that the CDC6-dependent
controlling mechanism can be physiological and operating in
intact cells. This suggests that it may tune the mitotic timing, at
least during early embryo development when such a control
seems important for synchronization of cleavages with develop-
mental program.
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